(234 days)
No
The device description and performance studies focus on chemical solutions and physical separation methods (density-gradient centrifugation), with no mention of AI, ML, or image processing.
No
This device is for the preparation and washing of sperm for use in assisted reproduction procedures; it does not treat a disease or condition.
No
Explanation: The device is used for the preparation and washing of sperm and for the separation of motile sperm from seminal fluid for use in assisted reproduction procedures. It does not diagnose any condition or disease.
No
The device is a chemical solution used for sperm preparation and separation, not a software program.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the preparation and washing of sperm and the separation of motile sperm from seminal fluid for use in assisted reproduction procedures. This is a process performed on the biological sample (semen) to prepare it for a subsequent procedure (assisted reproduction), not to diagnose a condition or provide information about a patient's health status.
- Device Description: The device consists of solutions used for density-gradient centrifugation and washing of sperm. These are reagents and media used in a laboratory procedure, not a test or assay designed to detect or measure a substance in a biological sample for diagnostic purposes.
- Lack of Diagnostic Claims: There are no claims or indications that the device is used to diagnose any condition, disease, or state of health.
- Performance Studies: The performance studies focus on the quality and effectiveness of the solutions in preparing and separating sperm (e.g., sperm assessment for motility, morphology, viability, purity, and integrity), not on the accuracy or reliability of a diagnostic measurement.
In vitro diagnostics are typically tests performed on biological samples (like blood, urine, or tissue) outside the body to provide information for the diagnosis, monitoring, or treatment of a disease or condition. This device is a tool used to prepare a biological sample for a procedure, not to perform a diagnostic test on it.
N/A
Intended Use / Indications for Use
SepaSperm Washing Solution is used for preparation and washing of sperm for use in assisted reprocedures. SepaSperm Washing Solution is not intended for use in intrauterine insemination procedures.
SepaSperm Solution is used for separation of motile sperm from seminal fluid for use in assisted reproduction procedures.
Product codes
MQL
Device Description
SepaSperm is used for preparation and washing of sperm and for separation of motile sperm from semen in assisted reproductive techniques.
The device includes two types of solutions used for density-gradient centrifugation:
- . SepaSperm Solution for sperm preparation and separation from semen, and
- . SepaSperm Washing Solution for sperm washing and preparation
Both solutions are provided in two sizes (100mL and 50mL bottles). This product is single-use only and includes no accessories. The provided sterile-filtered into a container that is sterilized by gamma irradiation.
SepaSperm Solution is offered in four different densities, determined by the amount of silica present:
- SepaSperm Solution 100% -
- -Lower laver solution 80%
- Middle layer solution 60% -
- -Upper layer solution 40%
SepaSperm Solution is composed of silica particles diluted with modified human tubal fluid (m-HTF) medium, with dextran and polyvinylpyrrolidone added. The m-HTF medium is a HEPES-buffered solution which is suitable for use in ambient conditions. All SepaSperm Solutions are provided with and without gentamicin. SepaSperm Solution has a shelf-life of six or 12 months for media without or with gentamicin, respectively.
The SepaSperm Washing Solution consists of m-HTF medium supplemented with dextran and polyvinylpyrrolidone. It contains no silica. SepaSperm Washing Solution is used to wash the prepared sperm and suspend the final pellet. SepaSperm Washing Solutions are provided with and without gentamicin. SepaSperm Washing Solution has a shelf-life of six or 12 months for media without or with gentamicin, respectively.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The following studies have been performed to support substantial equivalence to the predicate devices. Results confirm that the design inputs and performance specifications for the device are met.
- Shelf Life Performance Testing (Time 0 and end of shelf-life):
- o Appearance
- Specific gravity: 1.0600-1.1200 o
- pH, per USP : 7.2 7.6 o
- Osmolality, per USP : 270-300 mOsm/Kg o
- Endotoxin, per USP : =80% of control motility at 24h o
- Sterility, per USP : No microbial growth o
- Sterile filtration and Aseptic fill validation, per ISO 13408-1:2008(R2013) and ISO 13408-R 2:2003(R)2013)
- Transportation testing per ASTM D4169-16
- Bottle seal strength testing and containers performance testing per
- Sperm assessment for motility, morphology, viability, purity, and integrity before and after separation procedures to assess the effectiveness of the device when used in the three separation modes stated in device labeling.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 884.6180 Reproductive media and supplements.
(a)
Identification. Reproductive media and supplement are products that are used for assisted reproduction procedures. Media include liquid and powder versions of various substances that come in direct physical contact with human gametes or embryos (including water, acid solutions used to treat gametes or embryos, rinsing solutions, sperm separation media, supplements, or oil used to cover the media) for the purposes of preparation, maintenance, transfer or storage. Supplements are specific reagents added to media to enhance specific properties of the media (e.g., proteins, sera, antibiotics, etc.).(b)
Classification. Class II (special controls) (mouse embryo assay information, endotoxin testing, sterilization validation, design specifications, labeling requirements, biocompatibility testing, and clinical testing). The device, when it is phosphate-buffered saline used for washing, and short-term handling and manipulation of gametes and embryos; culture oil used as an overlay for culture media containing gametes and embryos; and water for assisted reproduction applications, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 884.9.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
September 26, 2019
Kitazato Corporation % Audrey Swearingen Regulatory Affairs Manager Emergo Global Consulting, LLC 2500 Bee Cave Road, Building 1, Suite 300 Austin, TX 78746
Re: K190199
Trade/Device Name: SepaSperm Washing Solution, SepaSperm Solution Regulation Number: 21 CFR 884.6180 Regulation Name: Reproductive media and supplements Regulatory Class: II Product Code: MQL Dated: August 26, 2019 Received: August 27, 2019
Dear Audrey Swearingen:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For Sharon M. Andrews Assistant Director DHT3B: Division of Reproductive. Gynecology and Urology Devices OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K190199
Device Name
SepaSperm Washing Solution, SepaSperm Solution
Indications for Use (Describe)
SepaSperm Washing Solution is used for preparation and washing of sperm for use in assisted reprocedures. SepaSperm Washing Solution is not intended for use in intrauterine insemination procedures.
SepaSperm Solution is used for separation of motile sperm from seminal fluid for use in assisted reproduction procedures.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary - K190199
1. Submitter Information
| Applicant: | Kitazato Corporation |
|---|---|
| Contact: | Mr. Futoshi Inoue |
| President and Representative Director | |
| Address: | 81 Nakajima, Fuji-shi |
| Shizuoka 416-0907 | |
| Japan |
2. Correspondent Information
| Contact: | Audrey Swearingen
Manager, Regulatory Affairs |
|----------|------------------------------------------------------------------------------------------------------|
| Address: | Emergo Global Consulting, LLC 2500 Bee
Cave Road
Building 1, Suite 300
Austin, TX 78746 USA |
| Phone: | (512) 327-9997 |
| Fax: | (512) 327-9998 |
| Email: | lst.aus.projectmanagement@ul.com |
3. Date prepared: September 23, 2019
4. Device Information
| Device Name: | SepaSperm Washing Solution, SepaSperm Solution | |
|---|---|---|
| Common Name: | Sperm processing media | |
| Regulation Number: | 21 CFR 884.6180 | |
| Regulation Name: | Reproductive media and supplements | |
| Regulatory Class: | Class II | |
| Product Code: | MQL (media, reproductive) |
5. Predicate Device Information
| Device Name: | Sydney IVF Sperm Medium, Sydney IVF Sperm Gradient Kit, Sydney IVF Spermient |
|---|---|
| 510(k) Number: | K152782 |
| Manufacturer: | William A. Cook Australia Pty Ltd. |
| Regulatory Class: | Class II |
| Product Code: | MQL (media, reproductive) |
The predicate device has not been subject to a design-related recall.
6. Device Description
SepaSperm is used for preparation and washing of sperm and for separation of motile sperm from semen in assisted reproductive techniques.
The device includes two types of solutions used for density-gradient centrifugation:
- . SepaSperm Solution for sperm preparation and separation from semen, and
- . SepaSperm Washing Solution for sperm washing and preparation
4
Both solutions are provided in two sizes (100mL and 50mL bottles). This product is single-use only and includes no accessories. The provided sterile-filtered into a container that is sterilized by gamma irradiation.
SepaSperm Solution is offered in four different densities, determined by the amount of silica present:
- SepaSperm Solution 100% -
- -Lower laver solution 80%
- Middle layer solution 60% -
- -Upper layer solution 40%
SepaSperm Solution is composed of silica particles diluted with modified human tubal fluid (m-HTF) medium, with dextran and polyvinylpyrrolidone added. The m-HTF medium is a HEPES-buffered solution which is suitable for use in ambient conditions. All SepaSperm Solutions are provided with and without gentamicin. SepaSperm Solution has a shelf-life of six or 12 months for media without or with gentamicin, respectively.
The SepaSperm Washing Solution consists of m-HTF medium supplemented with dextran and polyvinylpyrrolidone. It contains no silica. SepaSperm Washing Solution is used to wash the prepared sperm and suspend the final pellet. SepaSperm Washing Solutions are provided with and without gentamicin. SepaSperm Washing Solution has a shelf-life of six or 12 months for media without or with gentamicin, respectively.
7. Indications for Use
SepaSperm Washing Solution is used for preparation and washing of sperm for use in assisted reproduction
procedures. SepaSperm Washing Solution is not intrauterine insemination procedures.
SepaSperm Solution is used for separation of motile sperm from seminal fluid for use in assisted reproduction
procedures.
8. Comparison of Intended Use and Technological Characteristics with the Predicate Device
The table below lists the comparison of the indications for use and technological characteristics of the subject and predicate device.
| Manufacturer | Kitazato Corporation | William A. Cook Australia Pty Ltd. |
|---|---|---|
| Trade Name | SepaSperm Solution and | |
| SepaSperm Washing Solution | Sydney IVF Spermient, Sydney IVF | |
| Sperm Gradient Kit, and Sydney IVF | ||
| Sperm Medium | ||
| 510(k) Number | K190199 | K152782 |
Table 1: Comparison of Characteristics
5
| Indications for Use | SepaSperm Washing Solution is
used for preparation and washing
of sperm for use in assisted
reproduction procedures.
SepaSperm Washing Solution is
not intended for use in
intrauterine insemination
procedures.
SepaSperm Solution is used for
separation of motile
sperm from seminal fluid for use
in assisted reproduction
procedures. | Sydney IVF Sperm Gradient Kit and
Sydney IVF Spermient are intended for
use during in vitro fertilization
procedures to separate motile sperm from
seminal plasma.
Sydney IVF Sperm Medium is intended
for use during in vitro fertilization
procedures to process sperm. |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Materials of
Sperm
Separation
Solution | Silica, HEPES buffered salt
solution, D-glucose, water,
dextran, polyvinylpyrrolidone;
includes options with and
without gentamicin. | Not known |
| Materials of
Sperm
Washing
Component | Same as those of the SepaSperm
Solution (above), except that it
does not contain silica. | Not known |
| Volume | 50mL, 100mL | Sydney IVF Sperm Medium: 20 mL, 50
mL, and 100 mL
Sydney IVF Sperm Gradient Kit: 20 mL
and 50 mL
Sydney IVF Spermient: 200 mL and 100
mL |
| Solution
density (%
silica) | SepaSperm Solution: 40%,
60%, 80%, 100% | Sperm Gradient Kit: 40% and 80%;
Sydney IVF Spermient: 100% |
| Osmolality | 270-300 mOsm/kg | 285-295 mOsm/kg |
| pH | 7.2 - 7.6 | Sydney IVF Sperm Medium: 7.5-7.8
Sydney IVF Sperm Gradient Kit /Sydney
IVF Spermient: 7.3-7.5 |
| Sperm
Survival
Assay
(HSSA) | ≥80% of control motility at 24h | Performed, specification not known |
| Endotoxin | ≤0.25 EU/mL | : 7.2 7.6 o
- Osmolality, per USP : 270-300 mOsm/Kg o
- Endotoxin, per USP : : No microbial growth o
- Sterile filtration and Aseptic fill validation, per ISO 13408-1:2008(R2013) and ISO 13408-● 2:2003(R)2013)
- Transportation testing per ASTM D4169-16
- Bottle seal strength testing and containers performance testing per ●
- Sperm assessment for motility, morphology, viability, purity, and integrity before and after ● separation procedures to assess the effectiveness of the device when used in the three separation modes stated in device labeling.
10. Conclusion
The results of the performance testing described above demonstrate that the SepaSperm Washing Solution and SepaSperm Solution are as safe and effective as the predicate device and supports a determination of substantial equivalence.